share_log

GlaxoSmithKline | 6-K: Viiv Healthcare Presents Phase I Clinical Trial Findings of a Cabotegravir Long-Acting Injectable Investigational Formulation Allowing at Least Four Months Between Doses

GlaxoSmithKline | 6-K: Viiv Healthcare Presents Phase I Clinical Trial Findings of a Cabotegravir Long-Acting Injectable Investigational Formulation Allowing at Least Four Months Between Doses

葛蘭素史克 | 6-K：Viiv Healthcare公佈卡Cabotegravir長效注射劑研究配方的I期臨床試驗結果，兩次給藥間隔至少四個月
SEC announcement ·  03/05 19:13

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。